STAT3 and lung carcinoma: Chen and colleagues found that the inhibition of ATM using specific ATM inhibitor CP466722 or siRNA reduced JAK/STAT3 signaling and PD-L1 expression, thus inhibiting the EMT and metastatic potential of cisplatin-resistant lung cancer cells [70].